key: cord-0834127-jqfwamue authors: Mallon, P. W.; Tinago, W.; Garcia Leon, A.; McCann, K.; Kenny, G.; McGettrick, P.; Green, S.; Inzitiari, R.; Cotter, A.; Savinelli, S.; Feeney, E. R.; Doran, P. title: Dynamic change and clinical relevance of post-infectious SARS-CoV-2 antibody responses. date: 2021-01-26 journal: nan DOI: 10.1101/2021.01.24.20248381 sha: cc0dde9e1db3abbfab075368dcca28f83623dfc3 doc_id: 834127 cord_uid: jqfwamue Background: Although reports suggest that most individuals with COVID-19 develop detectable antibodies post infection, the kinetics, durability, and relative differences between IgM and IgG responses beyond the first few weeks after symptom onset remain poorly understood. Methods: Within a large, well-phenotyped, diverse, prospective cohort of subjects with and without SARS-CoV-2 PCR-confirmed infection and historical controls derived from cohorts with high prevalence of viral coinfections and samples taken during prior flu seasons, we measured SARS-CoV-2 serological responses (both IgG and IgM) using commercially available assays. We calculated sensitivity and specificity, relationship with disease severity and mapped the kinetics of antibody responses over time using generalised additive models. Results: We analysed 1,001 samples from 752 subjects, 327 with confirmed SARS-CoV-2 (29.7% with severe disease) spanning a period of 90 days from symptom onset. Sensitivity was lower (44.1-47.1%) early (<10 days) after symptom onset but increased to >80% after 10 days. IgM positivity increased earlier than IgG-targeted assays but positivity peaked between day 32 and 38 post onset of symptoms and declined thereafter, a dynamic that was confirmed when antibody levels were analysed, with more rapid decline observed with IgM. Early (<10 days) IgM but not IgG levels were significantly higher in those who subsequently developed severe disease (signal / cut-off 4.20 (0.75-17.93) versus 1.07 (0.21-5.46), P=0.048). Conclusions: This study suggests that post-infectious antibody responses in those with confirmed COVID-19 begin to decline relatively early post infection and suggests a potential role for higher IgM levels early in infection predicting subsequent disease severity. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of was first identified in December 2019 in Wuhan, China before rapidly becoming pandemic. Over and above the significant proportion of asymptomatic cases, the majority of symptomatic COVID-19 cases are mild. However, up to 20% of infections progress to severe disease, as classified by the World Health Organisation (WHO),[1] with comorbidities, male sex and older age associated with poorer outcomes. [2] It remains unclear to what extent infection with SARS-CoV-2 confers post-infectious immunity, either through humoral (antibody-mediated) or cellular (T-cell mediated) mechanisms. Emerging data suggest that many individuals, particularly with severe COVID-19, mount detectable anti-SARS-CoV-2 IgG responses within two weeks after infection, [3] with many factors influencing antibody responses including age, disease severity and time from onset of symptoms, with variable intensity and durability of serologic responses reported. [4, 5] Serology plays important roles in the diagnosis of many infections, both at an individual and population level, with early IgM responses used to detect recent infections and more persistent memory IgG responses used to estimate seroprevalence. However, given the uncertainties surrounding development and persistence of antibody responses to SARS-CoV-2, [6] the role of serology in diagnosis or surveillance of COVID-19 remains to be fully clarified. A number of commercial anti-SARS-CoV-2 serological assays report high sensitivity and specificity. However, their validation in real-world settings, taking into account the range of factors that affect serologic responses, including cross-reactivity against other chronic infections, has been limited. [7] Although several studies have compared commercially available serological assays in COVID-19, many have small sample sizes [8] or lack non-SARS-CoV-2 infected controls. [7, All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 26, 2021. ; https://doi.org/10.1101/2021.01.24.20248381 doi: medRxiv preprint 9] Additionally, inclusion of uninfected controls defined as not detected on SARS-CoV-2 PCR [10] raises the potential for false positive antibody tests to be misinterpreted in those with previous infection, particularly where detailed clinical information is lacking. Many other studies either have limited data on disease severity [11, 12] , or have over-representation of hospitalized patients with severe disease. In one systematic review only 4 of 40 studies included non-hospitalised patients, [13] which limits the generalisability of some observations, such as associations between higher antibody titres and disease severity. [14] In one of the largest studies to date, analysing 976 pre-pandemic blood samples and 536 blood samples from patients with SARS-CoV-2 infection, severity data was only available for 29%. [15] Lastly, although SARS-CoV-2 serological responses are dynamic, not all studies either report or account for time since symptom onset; in a recent Cochrane systematic review, 19 of 57 included studies did not stratify by time since symptom onset. [16] The same review found very little data beyond 35 days post onset of symptoms. To address these data gaps, we aimed to compare several different commercial SARS-CoV-2 serological assays in demographically, clinically diverse and well phenotyped clinical cohorts, to define the dynamic change in qualitative and quantitative antibody responses over time since symptom onset, and delineate the relative role of IgM versus IgG antibodies in relation to onset and severity of infection in clinical samples from individuals with and without COVID-19 infection. The All Ireland Infectious Diseases (AIID) Cohort study is a prospective, multicentre cohort enrolling patients attending clinical services for Infectious Diseases in Ireland. Subjects provide data on demographics (age, sex, ethnicity, smoking status), clinical characteristics (hospitalisation, date of symptoms onset, underlying conditions e.g. diabetes, malignancies) and laboratory results. COVID-19 disease severity was defined according to the WHO All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 26, 2021. ; https://doi.org/10.1101/2021.01.24.20248381 doi: medRxiv preprint guidance[1] and collapsed into severe and non-severe for analysis. Subjects also provided blood samples for bio-banking on up to three occasions. All subjects provide written, informed consent and the study is approved by local and national research ethics committees. For this analysis we included AIID Cohort participants who presented to the Mater Misericordiae University Hospital and St Vincent's University Hospital with symptoms consistent with COVID-19 between the 26th of March 2020 and the 10th of July 2020 with available biobanked samples. In addition, as controls, we included subjects with plasma samples biobanked prior to 2020 from the AIID Cohort and another longitudinal study of subjects with and without HIV infection, [17] including samples specifically taken during previous flu seasons from 2016 to 2019, as outlined in national statistics. [18, 19] Plasma, stored at -80°C and thawed in batches, underwent same-day serological testing in The Elecsys assay presents results as a cut-off index (COI), derived from comparison of All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 26, 2021. Continuous and categorical variables are summarised using median with interquartile range (IQR) and frequency/percentage respectively. Sensitivity and specificity along with their binomial exact 95% confidence intervals (CI) were used to describe the performance characteristics of the assays. Sensitivity was calculated based on samples from subjects who tested detected on SARS-CoV-2 PCR (SARS-CoV-2 Pos). Specificity was derived for two distinct groups (i) samples from subjects who presented for hospital care during the 2020 pandemic but who tested 'not detected' on SARS-CoV-2 PCR (SARS-CoV-2 Neg) and (ii) historical controls-subjects (Controls Pre-2020) that included subjects with and without chronic infections such as HIV and hepatitis C as well as subjects with biobanked serum samples taken during prior flu seasons between 2016 and 2019. Within the SARS-CoV-2 Pos group, assay sensitivity was also evaluated at different time periods after date of symptom onset; 0-10, 11-21, 21-42 and >42 days. We used scatter plots with superimposed curves fitted using generalised additive models (GAM), with either a Gaussian or binomial link function and time since symptom onset fitted as a spline, to depict the non-linear relationship between time from symptom onset with either (i) quantitative antibody levels or (ii) seropositivity rate as dependent variables respectively. We compared quantitative antibody responses (COI for Elecsys or S/CO for Abbott IgG and IgM assays, referred to as antibody 'levels') and positivity rate for the first two time periods post All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 26, 2021. ; https://doi.org/10.1101/2021.01.24.20248381 doi: medRxiv preprint symptoms onset (0-10 and 11-21 days) between subjects categorised into severe and nonsevere maximal disease stage attained using the Wilcoxon rank sum test and the chi-square test respectively. Overall sensitivity and specificity were compared between assays using the McNemar's chisquare test as previously described. [20, 21] Overall concordance between the assays was (Table 1) . Compared to the SARS-CoV-2 Neg group, the SARS-CoV-2 Pos group were more likely to be diabetic, have an underlying All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 26, 2021. ; https://doi.org/10.1101/2021.01.24.20248381 doi: medRxiv preprint malignancy and less likely to smoke. Although the majority of the SARS-CoV-2 Pos and SARS-CoV-2 Neg groups were admitted to hospital (71.8% and 79.9% respectively), within the SARS-CoV-2 Pos group, most (58%) experienced only mild disease, 12% moderate and 30% severe disease severity respectively. Overall, the sensitivity for all four assays was relatively low, ranging from 74.3% to 77.1% (Table 2) , with no significant difference in sensitivity between assays (Supplementary table 1 ). In contrast, all three IgG-targeted assays and the IgM assay were highly specific, ranging from 92.7% to 100% ( Table 2 ). The sensitivity of the three IgG-targeted assays increased considerably with time after onset of COVID-19 symptoms; 44.1% to 47.1% in samples collected ≤ 10 days post symptom onset increasing to a maximum sensitivity ranging from 86.5% to 90.5% in samples collected at >42 days post symptom onset, with no significant differences between the three assay ( Figure 1 , Table 3 ). In contrast, the Abbott IgM assay sensitivity increased from a low of 57.6% in the early (≤10 days) period to a high of 89.0% at 11-21 days post symptom onset, but notbaly decline to 68.5% >42 days post symptom onset (Figure 1 ). Merging Abbott Architect IgM and IgG positive responses into a single variable did not appreciably alter overall sensitivity (82.9% (95% C.I. 78.3, 86.8)) or specificity (98.3% (93.9, 99.8)) or at any of the timepoints analysed (data not shown). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Figure 1 ). There was a more rapid increase in the positivity rate with Abbott Architect IgM assay, with an earlier peak at day 23 post symptom onset (positivity rate 88.7% (95% CI 82.8; 92.8) Supplementary Figure 2 ). In addition, after day 23 from symptom onset, there was a more rapid decline in positivity rate with the Abbott IgM assay compared to the IgG assay ( Figure 2 ). Overall, median (IQR) antibody levels for the three IgG-targeted assays were 11.93 (1.66- IgG-targeted antibody levels increased after onset of symptoms, peaking at 47, 35 days and 36 days post symptoms onset for the Elecsys (peak COI of 32.9), Abbott Alinity (peak S/CO 8.2) and Abbott Architect (peak S/CO 5.4) respectively (Figure 3a-c) . The IgM antibody titres peaked earlier at 26 days and followed a more rapid decline thereafter relative to the other three assays (Figure 3d ). There were no significant differences in early IgG-targeted antibody levels (0-10 or 11-22 days post symptom onset) between subjects who developed severe versus non-severe COVID-19 infection (Figure 4, Supplementary table 2) . In contrast, early IgM antibody levels All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (Figure 4d, Supplementary table 3) . Within the SARS-CoV-2 Neg group, 9 (4.02% overall) returned a positive result on the Elecsys assay, of which 8 (3.57% overall) were also positive on both Abbott IgG assays. infection. Furthermore, we demonstrate declines in antibody levels of all assays after a peak that occurs quite early (5-6 weeks) post symptom onset. These data provide important insights into both the clinical utility of serology in managing SARS-CoV-2 infection as well All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 26, 2021. ; https://doi.org/10.1101/2021.01.24.20248381 doi: medRxiv preprint the limited longevity of antibody responses, which may have implications for post-infection immunity to SARS-CoV-2. Although overall assay sensitivity for all four assays was less than 80%, sensitivity was lower early after symptom onset and increased to levels consistently above 80% after day 11 and maintained beyond day 42 for all but the Abbott IgM assay, which decreased notably after day 42 to 68.5% (Table 3 ). These data are in keeping with previous studies and metanalyses that demonstrated lower assay sensitivity early after onset of symptoms [7, 11, 13, 16] and other studies that demonstrated high sensitivity in samples taken more than 2 weeks after symptom onset. In our analysis, significantly higher IgM levels early in infection (before day 10), but not levels of the other antibodies tested, were observed in subjects who developed severe COVID-19. This is in contrast to a previous smaller study that showed higher IgG levels (but All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 26, 2021. ; https://doi.org/10.1101/2021.01.24.20248381 doi: medRxiv preprint not IgM) in subjects with severe compared to asymptomatic SARS-CoV-2 infection, however this previous study did not include as heterogeneous a study population as our analysis. Interestingly, the only other study to report on kinetics of IgM and IgG early into infection (N=23, 11 with moderate and 12 with severe infection) also demonstrated higher early IgM but not IgG levels in more severe disease. [22] These data, confirmed within our large, diverse population suggest a potential role for early measurement of IgM in identifying those presenting with symptoms who are at greater risk of developing severe COVID-19. Our results add to the body of data showing the high specificity of the serological assays tested. In particular, we showed little cross-reactivity with historical samples from populations with high prevalence of common viral co-infections as well as those taken during previous outbreaks of reported community influenza-like illnesses in Ireland. Of note, when we analysed cases of positive antibody responses in subjects hospitalised but not detected by SARS-CoV-2 PCR we identified a majority that presented with symptoms consistent with COVID-19 where no alternative diagnosis was established. This suggests an additional clinical use for serological testing in aiding clinical diagnosis in these circumstances. Our study has limitations. Although we measured serological responses, we do not have data on corresponding functional immunity, important when interpreting the clinical relevance of the observed decline in antibody levels. Although we analysed historical samples, we did not have data on confirmed influenza in these subjects nor did we routinely test the SARS-CoV2 Pos and Neg groups for other co-infections. Despite these limitations, this study, one of the largest and most detailed analyses of the performance and kinetics of anti-SARS-CoV-2 antibody responses, suggests higher, early IgM responses in those who develop more severe COVID-19. The early decline in antibody levels, as early as five weeks post symptom onset, contribute to an increasing concern that post-infectious immunity to SARS-CoV-2 infection may be time limited. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. for the antibody reactions. The funding sources had no role in the study design, recruitment, data collection or analysis of the study results. Representatives from Abbott Diagnostics were provided an opportunity to review and comment on the manuscript prior to submission. The authors wish to thank all study participants and their families for their participation and support in the conduct of the All Ireland Infectious Diseases Cohort Study. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 26, 2021. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 26, 2021. ; When measured in all available samples, sensitivity for all assays was lower than specificity. SAR-CoV-2; severe acute respiratory syndrome coronavirus 19. Ab; antibody. CI, confidence interval. * IgM was only measured in the control samples from prior flu-seasons (n=116) and data were available for 150 of 152 samples for each of the other three assays. The proportion of individuals with SARS-CoV-2 PCR-detected diagnosis of COVID-19 with positive antibody responses was higher after 10 days from symptom onset for all assays. Ab; antibody. CI, confidence interval. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 26, 2021. Log; logarithmic All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 26, 2021. ; Figure 1 . Sensitivity of serological assays based on time periods from onset of symptoms. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 26, 2021. ; Supplementary figure 1. Rates of seropositivity to the Abbott Architect IgG assay and time from symptom onset. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 26, 2021. ; https://doi.org/10.1101/2021.01.24.20248381 doi: medRxiv preprint All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 26, 2021. ; World Health Organisation) Clinical Management of COVID-19 Interim Guidance Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Molecular and serological characterization of SARS-CoV-2 infection among COVID-19 patients Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months The trinity of COVID-19: immunity, inflammation and intervention Comparison of eight commercial, high-throughput, automated or ELISA assays detecting SARS-CoV-2 IgG or total antibody Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients Quantification of SARS-CoV-2 antibodies with eight commercially available immunoassays Determination of SARS-CoV-2 antibodies with assays from Diasorin, Roche and IDvet Assessment of SARS-CoV-2 serological tests for the diagnosis of COVID-19 through the evaluation of three immunoassays: Two automated immunoassays (Euroimmun and Abbott) and one rapid lateral flow immunoassay (NG Biotech) Comparison of the Elecsys(R) Anti-SARS-CoV-2 immunoassay with the EDI enzyme linked immunosorbent assays for the detection of SARS-CoV-2 antibodies in human plasma Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2020. 15. National S-C-SAEG. Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison Antibody tests for identification of current and past infection with SARS-CoV-2 Relative contribution of HIV infection, demographics and body mass index to bone mineral density Influenza and Other Seasonal Respiratory Viruses in Ireland Influenza and Other Seasonal Respiratory Viruses in Ireland McNemar chi2 test revisited: comparing sensitivity and specificity of diagnostic examinations Data are median (IQR) unless otherwise stated. HBV status defined as sAg positive Human immunodeficiency virus. HCV; hepatitis C virus. HBV; hepatitis B virus. CRP; Creactive protein. WHO; World Health Organisation. N; number. *Disease severity assigned according to WHO criteria 4 and 15 SARS-CoV-2 Pos and SARS-CoV-2 Neg respectively. § Ferritin missing in 7 and 18 SARS-CoV-2 Pos and SARS-CoV-2 Neg respectively Clinical characteristics of subjects in the SARS-CoV-2 Neg group with positive IgG antibody Previous admission in late 2019 with perihilar parenchymal changes noted on CXR. 70-80 Male Presented with clinical diagnosis of pneumonia but not tested for SARS-CoV-2 infection. Serology assessed as part of an outpatient post-COVID ('Long COVID') clinic. 40-50 Female Presented 12 days post symptom onset. Influenza-like illness. No cause found. Close contact of a confirmed case. NP not detected on three occasions. 30-40 Male Risk through occupational exposure. Close contact of a confirmed case. NP swab negative. 40-50 Male Presented with an influenza-like illness and systemic inflammatory response. Multiple NP swabs not detected. High clinical suspicion for COVID-19 infection. 70-80 Male Presented with breathlessness Female Presented day 21 after symptom onset with influenza-like illness. NP swab not detected. Diagnosed with viral myocarditis. 50-60 Male Risk through occupational exposure. Presented day 14 after symptom onset with cough and breathlessness. WHO Critical Severity grading. NP swab negative on three occasions Age ranges only provided to ensure anonymity. NP; nasopharyngeal. ICU; intensive care unit. CXR; chest x-ray. WHO; World Health Organisation